Molecular Pharmacology and Therapeutics Program, University of Minnesota, Minneapolis 55455, United States; Department of Pharmacology, University of Minnesota, Minneapolis 55455, United States.
Masonic Cancer Center, University of Minnesota, Minneapolis 55455, United States.
J Steroid Biochem Mol Biol. 2024 Oct;243:106575. doi: 10.1016/j.jsbmb.2024.106575. Epub 2024 Jun 29.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks expression of the nuclear steroid receptors that bind estrogens (ER) and progestogens (PRs) and does not exhibit HER2 (Human epidermal growth factor 2) receptor overexpression. Even in the face of initially effective chemotherapies, TNBC patients often relapse. One primary cause for therapy-resistant tumor progression is the activation of cellular stress signaling pathways. The glucocorticoid receptor (GR), a corticosteroid-activated transcription factor most closely related to PR, is a mediator of both endocrine/host stress and local tumor microenvironment (TME)-derived and cellular stress responses. Interestingly, GR expression is associated with a good prognosis in ER+ breast cancer but predicts poor prognosis in TNBC. Classically, GR's transcriptional activity is regulated by circulating glucocorticoids. Additionally, GR is regulated by ligand-independent signaling events. Notably, the stress-activated protein kinase, p38 MAP kinase, phosphorylates GR at serine 134 (Ser134) in response to TME-derived growth factors and cytokines, including HGF and TGFβ1. Phospho-Ser134-GR (p-Ser134-GR) associates with cytoplasmic and nuclear signaling molecules, including 14-3-3ζ, aryl hydrocarbon receptors (AhR), and hypoxia-inducible factors (HIFs). Phospho-GR/HIF-containing transcriptional complexes upregulate gene sets whose protein products include the components of inducible oncogenic signaling pathways (PTK6) that further promote cancer cell survival, chemoresistance, altered metabolism, and migratory/invasive behavior in TNBC. Recent studies have implicated liganded p-Ser134-GR (p-GR) in dexamethasone-mediated upregulation of genes related to TNBC cell motility and dysregulated metabolism. Herein, we review the tumor-promoting roles of GR and discuss how both ligand-dependent and ligand-independent/stress signaling-driven inputs to p-GR converge to orchestrate metastatic TNBC progression.
三阴性乳腺癌(TNBC)是一种侵袭性乳腺癌亚型,缺乏与雌激素(ER)和孕激素(PRs)结合的核甾体受体表达,并且不表现出 HER2(人表皮生长因子 2)受体过表达。即使在最初有效的化疗情况下,TNBC 患者仍经常复发。治疗耐药肿瘤进展的一个主要原因是细胞应激信号通路的激活。糖皮质激素受体(GR)是一种与 PR 最密切相关的皮质激素激活转录因子,是内分泌/宿主应激和局部肿瘤微环境(TME)衍生和细胞应激反应的介质。有趣的是,GR 表达与 ER+乳腺癌的良好预后相关,但预测 TNBC 的预后不良。经典上,GR 的转录活性受循环糖皮质激素调节。此外,GR 受配体非依赖性信号事件调节。值得注意的是,应激激活的蛋白激酶 p38 MAP 激酶在 TME 衍生的生长因子和细胞因子(包括 HGF 和 TGFβ1)的作用下,在丝氨酸 134(Ser134)磷酸化 GR。磷酸化 Ser134-GR(p-Ser134-GR)与细胞质和核信号分子结合,包括 14-3-3ζ、芳香烃受体(AhR)和缺氧诱导因子(HIFs)。磷酸化-GR/HIF 包含的转录复合物上调基因集,其蛋白质产物包括诱导致癌信号通路(PTK6)的组成部分,进一步促进 TNBC 中癌细胞的存活、化疗耐药性、代谢改变和迁移/侵袭行为。最近的研究表明,配体结合的 p-Ser134-GR(p-GR)在地塞米松介导的与 TNBC 细胞迁移和代谢失调相关的基因上调中起作用。在此,我们综述了 GR 的肿瘤促进作用,并讨论了配体依赖性和配体非依赖性/应激信号驱动的输入如何协同作用以协调转移性 TNBC 进展。